Novel presenilin mutations within Moroccan patients with Early-Onset Alzheimer's Disease.
Alzheimer's disease (AD) is a progressive brain disorder that causes gradual and irreversible loss of higher brain functions and is the most common cause of dementia in the elderly, as assessed by autopsy and clinical series. Furthermore, it has an annual incidence of approximately 3% in the 65-74-year-old age group. This incidence rate doubles with every increment of 5 years above the age of 65. In Morocco, AD affects almost 30,000 individuals and this number will possibly increase to 75,000 by 2020 (projections of the World Health Organization (WHO)). Genetically, AD is caused by a mutation in one of at least 3 genes: presenilin 1 (PS1), presenilin 2 (PS2) and the amyloid precursor protein (APP). Most cases are late onset and apparently sporadic, most likely as a result of a combination of environmental and non-dominant genetic factors. In Morocco, the genes predisposing individuals to AD and predicting disease incidence remain elusive. The purpose of the present study was to evaluate the genetic contribution of mutations in PS1 and PS2 genes to familial early-onset AD cases and sporadic late-onset AD cases. Seventeen sporadic late-onset AD cases and eight familial early-onset AD cases were seen at the memory clinic of the University of Casablanca Neurology Department. These patients underwent standard somatic neurological examination, cognitive function assessment, brain imaging and laboratory tests. Direct sequencing of each exon in PS1 and PS2 genes was performed on genomic DNA of AD patients. Further, we identified 1 novel frameshift mutation in the PS1 gene and 2 novel frameshift mutations in the PS2 gene. Our mutational analysis reports a correlation between clinical symptoms and genetic factors in our cases of Early-Onset Alzheimer's Disease (EOAD). These putative mutations cosegregate with affected family members suggesting a direct mutagenic effect.
Laboratory of Medical Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco. Electronic address: elkadmiri1979@gmail.com.
N
N
El Kadmiri
Montreal Heart Institute and Université de Montréal, Montreal, Canada.
N
N
Zaid
Montreal Heart Institute and Université de Montréal, Montreal, Canada.
Y
Y
Zaid
Montreal Heart Institute and Université de Montréal, Montreal, Canada.
A
A
Tadevosyan
Montreal Heart Institute and Université de Montréal, Montreal, Canada.
A
A
Hachem
Montreal Heart Institute and Université de Montréal, Montreal, Canada.
M-P
MP
Dubé
Laboratory of Medical Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco.
K
K
Hamzi
Laboratory of Medical Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco; Department of Neurology, CHU IBN ROCHD, Casablanca, Morocco.
B
B
El Moutawakil
Laboratory of Medical Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco; Department of Neurology, CHU IBN ROCHD, Casablanca, Morocco.
I
I
Slassi
Laboratory of Medical Genetics and Molecular Pathology, Faculty of Medicine and Pharmacy, University Hassan II, Casablanca, Morocco.
S
S
Nadifi
D017668:Age of Onset; D000544:Alzheimer Disease / Q000235:genetics* / Q000503:physiopathology; D000595:Amino Acid Sequence; D004252:DNA Mutational Analysis; D005091:Exons; D005190:Family; D005260:Female; D016368:Frameshift Mutation; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009018:Morocco; D010375:Pedigree; D053764:Presenilin-1 / Q000235:genetics*; D053766:Presenilin-2 / Q000235:genetics*
C508853:PSEN1 protein, human; C508861:PSEN2 protein, human; D053764:Presenilin-1; D053766:Presenilin-2
Alzheimer’s disease; Moroccan patients; PS1 PS2 genes; frameshift mutations